|
Sep 23
|
EMA Committee Endorses AbbVie's Elahere in Ovarian Cancer
|
|
Sep 22
|
Is AbbVie (NYSE:ABBV) A Risky Investment?
|
|
Sep 10
|
Health Canada Approves AbbVie's CONSTELLA® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients 6 to 17 Years of Age
|
|
Sep 9
|
Why AbbVie (ABBV) Outpaced the Stock Market Today
|
|
Sep 9
|
3 Things You Need to Know if You Buy AbbVie Stock Today
|
|
Sep 9
|
AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs
|
|
Sep 8
|
3 No-Brainer Dividend Stocks to Buy in September
|
|
Sep 6
|
AbbVie Declares Quarterly Dividend
|
|
Sep 5
|
AbbVie Insiders Sell US$56m Of Stock, Possibly Signalling Caution
|
|
Sep 5
|
Got $1,000? 3 Healthcare Stocks to Buy and Hold Forever
|
|
Sep 4
|
AbbVie Stock Up Almost 20% in 3 Months: Buy, Sell or Hold?
|
|
Sep 4
|
AbbVie's VRAYLAR® (cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of Schizophrenia
|
|
Sep 4
|
Is AbbVie Inc. (ABBV) the Best Cancer Stock to Buy Now?
|
|
Sep 3
|
AbbVie (ABBV) Gains As Market Dips: What You Should Know
|
|
Aug 29
|
Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results
|
|
Aug 29
|
Why Is Pfizer (PFE) Down 5.9% Since Last Earnings Report?
|
|
Aug 29
|
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
|
|
Aug 29
|
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
|
|
Aug 29
|
Bull Market Buys: 3 Dividend Stocks to Own for the Long Run
|
|
Aug 28
|
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
|